<DOC>
	<DOCNO>NCT01668004</DOCNO>
	<brief_summary>The objective study determine difference annual incidence rate uveitis attack participant ankylose spondylitis ( AS ) start initial anti-TNF therapy treatment golimumab ( GLM ) .</brief_summary>
	<brief_title>The Incidence Extra-Articular Manifestations Participants With Ankylosing Spondylitis Treated With Golimumab ( MK-8259-012 )</brief_title>
	<detailed_description>This open-label , history-controlled , multi-site study GLM participant AS . For evaluation primary study outcome measure , participant serve control . The period start treatment anti-tumor necrosis factor ( TNF ) agent serve historical control incidence extra-articular manifestation , review medical record do previous 1-year period . Each participant participate study approximately 12 month time participant sign Informed Consent Form final contact . After screen , two four week study start , participant receiving study treatment approximately 12 month , depend response GLM 3 month . All participant follow minimum 12 month , irrespective duration GLM treatment .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>May treat GLM prior study enrollment Must able provide retrospective data concern extraarticular manifestation episodes recall period least 12 month prior antiTNF use Must definite AS accord modify New York criteria Netherlands Must candidate treatment antiTNF agent accord Assessment SpondyloArthritis International Society ( ASAS ) consensus Must able adhere dose visit schedule Any exclusion criterion state Summary Product Characteristics golimumab Use investigational biological chemical agent within 30 day 2 halflives ( whichever long ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>